×
Back to Agenda
Session 4 Track C: Personalized Medicine
Session Chair(s)
Karen Feltmate
President, Redstone Health Group, Inc., Canada
Session 4 Track C: Personalized Medicine
Learning Objective : 1) Understand the latest technological advancements in personalized medicine technology 2) Evaluate cost/benefit drivers for patient populations 3) Identify existing approved biomarkers and the implications of biomarker regulatory approval on product commercialization 4) Describe reimbursement considerations for personalized medicine based technologies in the health care arena
Speaker(s)
Laura Durno, MS, MSC
Acting Chief, Viral Vaccines Division, Biologics and Genetic Therapies Directorate, Health Canada, Canada
Session Co-Chair
Stephen F. Amato, PHD, RAC
Managing Director of East Coast Operations, Cardinal Health Regulatory Sciences, United States
The Keys to a Successful Personalized Medicine Strategy
George Wyatt
Managing Director, Wyatt Health Management, Canada
Speaker
Katherine M. Soltys, MD
Director, Office of Clinical Trials, Pharmaceutical Drug Directorate, Health Canada, Canada
Speaker
Have an account?